newsfilter
← Latest News
FDA Press Releases·

FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide

  • The FDA launched the Global Reliance Disclosure Program (GRDP) on October 30, 2026, to enable efficient sharing of minimally redacted approval packages with foreign regulatory authorities.
  • The program allows companies to share FDA scientific assessments with non-U.S. regulators, facilitating reliance on FDA reviews to accelerate patient access while preserving national regulatory sovereignty.
  • Initial GRDP availability is limited to PEPFAR tentative approvals for lenacapavir, excluding abbreviated new drug application products.
  • The FDA plans to expand the GRDP in January 2027 to cover all novel drugs & biologics, including New Molecular Entity NDAs & 351(a) BLAs.
  • A separate pathway launching in early 2027 will allow expedited requests for minimally redacted packages for already approved & licensed U.S. products.
  • Applicants must request participation within 10 calendar days of approval & confirm submission to a foreign authority to receive a minimally redacted package under the GRDP.
  • Requests for purposes other than supporting foreign marketing applications must be submitted via the Freedom of Information Act (FOIA).
  • The initiative aims to bridge the gap between high-capacity country approvals & patient access in lower-resource settings by reducing duplicative reviews.
  • FDA officials stated the program reflects America First policies & collaborative leadership to advance global health standards & security.